SciCombinator

Discover the most talked about and latest scientific content & concepts.

R Arranz, A García-Noblejas, C Grande, J Cannata-Ortiz, JJ Sánchez, JA García-Marco, C Aláez, J Pérez-Calvo, P Martínez-Sánchez, B Sánchez-González, MA Canales, E Conde, A Martín, E Arranz, MJ Terol, A Salar and D Caballero
Abstract
The prognosis for fit patients with mantle cell lymphoma has improved with intensive strategies. Currently, the role of maintenance/consolidation approaches is being tested as relapses continue appearing. In this trial we evaluated the feasibility, safety and efficacy of R-Hyper-CVAD alternating with R-MtxAraC followed by consolidation with 90Y-Ibritumomab-Tiuxetan. Patients received 6 cycles followed by a single dose of 90Y-Ibritumomab-Tiuxetan. Thirty patients were enrolled. Median age was 59 years. Twenty four patients finished the induction treatment, 23 achieved complete remission (77%, 95% confidence interval 60-93) and one patient had progressive disease (3%). Eighteen patients (60%), all in complete remission, received consolidation. In the intent- to- treat population, failure free, progression free and overall survival at 4 years were 40 % (95% confidence interval 20.4-59.6), 52% (95% confidence interval 32.4-71.6) and 81% (95% confidence interval 67.28-94.72), respectively. For patients who received consolidation, failure free and overall survival were 55% (95% confidence interval 31.48&-78.52) and 87% (95% confidence interval 70-100), respectively. Hematological toxicity was significant during induction and responsible for one death (3.3%). After consolidation, grade 3-4 neutropenia and thrombocytopenia were observed in 72% and 83% of patients, with median duration of 5 and 12 weeks, respectively. Six (20%) patients died, 3 due to secondary malignancies (myelodisplastic syndrome and bladder and rectum carcinomas). In conclusion, our experience with R-Hyper-CVAD/R-MtxAraC followed by consolidation with 90Y-Ibritumomab-Tiuxetan is efficacious although less feasible than expected. The unacceptable toxicity observed, specially secondary malignancies, advise against the indication of this strategy. Trial registration: clinical.gov identifier: NCT2005-004400-37.
Tweets*
0
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
6
Concepts
Lung cancer, Interval finite element, Chemotherapy, Hematological malignancy, Types of cancer, Cancer, Normal distribution, Mantle cell lymphoma
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com